2 results about "Iron Chelator" patented technology

The present invention relates to products and compositions and their uses. In particular, the invention relates to nucleic acid products that interfere with or inhibit the expression of the TMPRSS6 gene in combination with one or more iron chelators and possibly other active agents, as well as to therapeutic uses such as the treatment of hemochromatosis, porphyria, and blood disorders such as beta-thalassemia, sickle cell anemia, and transfusion iron overload or myelodysplastic syndrome, as well as infections and mortality not related to relapses associated with bone marrow transplantation.

The application discloses a controllable release gallium-iron chelator composite nanohydrogel and a preparation method and application thereof. The nanohydrogel is formed by compounding gallium ions, iron chelators and a suitable polymer carrier, and can realize time and space controllable release. The nanohydrogel can first deplete the available iron of pathogens in an infection or inflammation microenvironment, induce the iron starvation response of the pathogens, and then slowly release gallium ions to simulate the role of iron, enter the pathogen cells and interfere with the iron-dependent metabolism, so as to synergistically play the roles of anti-infection and protection of host cells. The nanohydrogel can still maintain antibacterial activity in a high iron environment of pathogens through a double iron capture mechanism, and can inhibit iron-dependent cell death (such as ferroptosis) and inflammation cascade reaction of the host. The nanohydrogel has good biocompatibility, organ targeting and controllable release characteristics, can be prepared into a local drug preparation or a systemic delivery preparation, is suitable for prevention and / or treatment of diseases related to fungal or bacterial infection, and has a significant application prospect.